Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by juniper88on Mar 21, 2019 7:09am
205 Views
Post# 29515357

RE:RE:RE:RE:RE:RE:RE:Trogarzo price increase

RE:RE:RE:RE:RE:RE:RE:Trogarzo price increase
SPCEO1 wrote: . I think that likely reflects the one worry I have had all along which is just how far up the MDR chain the doctors would go in prescribing Trogarzo. Would they give it only to those who have completely run out of options (that seems to be the case in most instances) or would they recognize that the earlier Trogarzo is prescribed as a patient gets more and more MDR, the better the result (in terms of improving CR4 cell count, etc). The latter does not seem to be happening.



To me it makes sense to start with the most sick.  There is not much to loose with them. But perhaps once they see how well the drug works they will move on to the bit less sick.  I don't believe that most doctors would be so full of themselves that they want to be to puzzle solving hero rather what is best longterm for their patients.  Just like we could not predict the intial uptake it would be difficult to predict what will happen now that we are in the "second wave."  Good or bad.  Let's see.
Bullboard Posts